JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
LGD-4033, also known as Ligandrol is a non-steroidal selective androgen receptor modulator (SARM) which has highly potent that with its molecular structure and chemical composition, helps in binding itself to the androgen receptors. Unlike steroidal compounds, SARMs are also studied as a function of the molecules' receptor selectivity profiles and tissue-specific signaling behavior in androgen-responsive target tissues. LGD-4033 is examined as a research compound for studying androgen receptor binding dynamics, transcriptional regulation, and downstream signaling pathways associated with musculoskeletal cellular models.
LGD-4033 was first discovered by Ligand Pharmaceuticals and later licensed to Viking Therapeutics, which has continued to attract academic attention due its chemical structure and potential applications. Research literature has concentrated on its non-steroidal chemical structure, receptor interaction specificity and activity in modulating signaling, as an aspect of the study of androgen receptor signaling biology. At this time, LGD-4033 for sale is only available as research and educational tools provided by Element CRP. The material is strictly for laboratory purposes and not approved for human or animal consumption, or into food, drug-based or cosmetic applications.
From Pubchem
IUPAC Name:4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrileSynonym: 1165910-22-4, LigandrolMolecular Formula: C14H12F6N2OMolecular Weight: 338.25 g/molCAS Number: 1165910-22-4PubChem CID: 44137686
LGD-4033 is being evaluated in molecular studies as a selective androgen receptor modulator for the prevention of muscle wasting with skeletal muscle–related cellular systems. Mitochondrial enzyme abundance, metabolic flux, and microvascular-related factors involved in organization of the muscle fibers are modulated by hormone sensitive signaling pathways. From research studies, changes in enzymatic makers of oxidative and glycolytic metabolism such as citrate synthase and Lactate dehydrogenase have been reported after interaction with the androgen receptor.
Experimental studies additionally investigate dose-dependent receptor activation profiles and their relationship to the handling of intracellular lipid, capillary signaling, and changes in metabolic pathways adopted in the context of particular muscle fiber characteristics. In these studies significance is based on signaling kinetics, receptor sensitivity and transcriptional fluctuations instead of functional or phenotype-driven interpretation.
LGD-4033 is also examined in research settings for its interaction with androgen receptor signaling networks involved in bone architecture regulation. Bone-associated cellular pathways coordinate trabecular organization, mineral deposition, and structural turnover through hormonally responsive transcriptional mechanisms. Investigative models explore changes in trabecular signaling parameters across femoral, vertebral, and tibial regions in response to selective androgen receptor modulation.
Research focuses on receptor selectivity, dose-dependent signaling thresholds, and potential off-target pathway engagement that may influence structural signaling balance within bone-related molecular systems.
LGD-4033 is referenced in signaling research exploring androgen receptor involvement in skeletal repair–associated molecular pathways. These investigations analyze receptor-mediated regulation of extracellular matrix components, collagen synthesis–related markers, and bone turnover–associated signaling indicators.
Pathway-level evaluations emphasize the coordination between androgen receptor transcriptional activity, anabolic–catabolic signaling balance, and metabolic pathway integration, without reference to recovery, performance, or clinical relevance.
LGD-4033 is used in investigational metabolic and toxicological studies development to evalualate what are known as off-target signaling effects of hepatic enzyme systems. Studied are changes in the liver biochemical-related signaling pathways involving cytochrome P450-mediated metabolism, transaminase-linked signal cascades and bilirubin processing activities.
These findings further add to our understanding of the in vivo distribution, metabolic processing and systemic pharmacological modulation selective androgen receptor modulator profiles at homeostasis.
LGD-4033 is a non-steroidal SARM developed to be used in scientific studies regarding molecular properties of receptor binding, tissue-selective ways of action, and effective transcriptional activation. Its value as molecular probe for musculoskeletal signaling networks, bone-related regulatory pathways and metabolic enzymes interactions at the cellular and biochemical level is being currently investigated.
At Element CRP, LGD-4033 for sale is supplied exclusively for research and educational purposes. The compound is intended strictly for laboratory investigation and is not approved for human or animal use, ingestion, or application in food, drug, or cosmetic products. Buy LGD-4033 if you are a qualified researcher.
LGD-4033 is a non-steroidal small-molecule selective androgen receptor modulator with high binding affinity at the androgen receptor and tissue-selective transcriptional response profile. Its structural format supports reliable performance in cell culture systems used for nuclear receptor pharmacology research.
Cell-based research with LGD-4033 examines AR binding affinity, ligand-induced receptor conformational changes, and tissue-selective transcriptional outputs in LNCaP prostate, C2C12 myoblast, and osteoblast cell models. Standard pharmacological readouts include AR-driven reporter gene assays and coregulator recruitment profiling.
Element CRP supplies this product at 10mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
